

Stefania Cerri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9389457/publications.pdf>

Version: 2024-02-01

37
papers

1,753
citations

331642
21
h-index

377849
34
g-index

37
all docs

37
docs citations

37
times ranked

3136
citing authors

#	ARTICLE	IF	CITATIONS
1	Fibrosing interstitial lung disease in primary Sjogren syndrome. Joint Bone Spine, 2021, 88, 105237.	1.6	11
2	Differences between Acute Exacerbations of Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases. Diagnostics, 2021, 11, 1623.	2.6	3
3	Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Internal Medicine Journal, 2020, 50, 1085-1090.	0.8	75
4	Interstitial pneumonia with autoimmune features: A single center prospective follow-up study. Autoimmunity Reviews, 2020, 19, 102451.	5.8	34
5	Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review. Journal of Clinical Medicine, 2020, 9, 407.	2.4	40
6	Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease. Case Reports in Medicine, 2020, 2020, 1-4.	0.7	9
7	Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature. Journal of Thoracic Disease, 2019, 11, 1621-1628.	1.4	45
8	Clinical differences in sarcoidosis patients with and without lymphoma: a single-centre retrospective cohort analysis. European Respiratory Journal, 2019, 54, 1802470.	6.7	10
9	Management of Idiopathic Pulmonary Fibrosis. , 2018, , 55-63.		1
10	Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement. Clinical Rheumatology, 2017, 36, 1261-1268.	2.2	57
11	Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report. Journal of Medical Case Reports, 2016, 10, 127.	0.8	2
12	Pulmonary Carcinosarcoma Arising in the Framework of an Idiopathic Pulmonary Fibrosis. Lung, 2016, 194, 171-173.	3.3	4
13	Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease. Autoimmunity Reviews, 2016, 15, 61-70.	5.8	70
14	Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. BMC Medicine, 2015, 13, 277.	5.5	23
15	Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline. Reumatismo, 2015, 67, 149-155.	0.9	4
16	Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study. Respiratory Medicine, 2015, 109, 904-913.	2.9	72
17	Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review. Internal and Emergency Medicine, 2015, 10, 401-411.	2.0	37
18	A Quantitative Proteomic Approach to Identify Significantly Altered Protein Networks in the Serum of Patients with Lymphangioleiomyomatosis (LAM). PLoS ONE, 2014, 9, e105365.	2.5	14

#	ARTICLE	IF	CITATIONS
19	Fibulin-1 Predicts Disease Progression in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2014, 146, 1055-1063.	0.8	42
20	Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respiratory Medicine, 2013, 107, 249-255.	2.9	84
21	Lung cancer in scleroderma: Results from an Italian rheumatologic center and review of the literature. Autoimmunity Reviews, 2013, 12, 374-379.	5.8	50
22	The big clinical trials in idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2012, 18, 428-432.	2.6	38
23	Clinical trials in idiopathic pulmonary fibrosis: where we have been and where we are going. Current Respiratory Care Reports, 2012, 1, 216-223.	0.6	0
24	Sarcoidosis: Challenging Diagnostic Aspects of an Old Disease. American Journal of Medicine, 2012, 125, 118-125.	1.5	43
25	Genetic testing in diffuse parenchymal lung disease. Orphanet Journal of Rare Diseases, 2012, 7, 79.	2.7	8
26	Management of Idiopathic Pulmonary Fibrosis. Clinics in Chest Medicine, 2012, 33, 85-94.	2.1	9
27	Emerging drugs for idiopathic pulmonary fibrosis. Expert Opinion on Emerging Drugs, 2011, 16, 341-362.	2.4	21
28	Role Of The QFT-IT Assay For The Diagnosis Of Latent Tuberculosis Infection Among Adult Immigrants. , 2011, , .		0
29	Genetic commonality between inflammatory bowel disease and sarcoidosis: the beginning of the end or the end of the beginning?. European Respiratory Journal, 2011, 37, 489-491.	6.7	7
30	Human Mucosal Associated Invariant T Cells Detect Bacterially Infected Cells. PLoS Biology, 2010, 8, e1000407.	5.6	563
31	Non-steroid agents for idiopathic pulmonary fibrosis. The Cochrane Library, 2010, , CD003134.	2.8	103
32	Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients. Chest, 2009, 136, 198-204.	0.8	137
33	Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT. <i>TB</i> assay. Expert Review of Respiratory Medicine, 2008, 2, 253-260.	2.5	12
34	Rifabutin for treating pulmonary tuberculosis. The Cochrane Library, 2007, , CD005159.	2.8	45
35	Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice. Journal of Infection, 2007, 54, e169-e174.	3.3	22
36	Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. Leukemia, 2006, 20, 379-381.	7.2	17

#	ARTICLE	IF	CITATIONS
37	Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis. Respiratory Medicine, 2004, 98, 1035-1044.	2.9	41